Biotech By Adam Feuerstein and Damian Garde Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s
Biotech By Adam Feuerstein A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Biotech By Damian Garde and Adam Feuerstein Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment
Business By Rebecca Robbins Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco
First Opinion By Dennis J. Selkoe Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs
Health By Damian Garde Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s
Biotech By Adam Feuerstein, Damian Garde, and Meg Tirrell An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug
Biotech By Matthew Herper, Adam Feuerstein, and Damian Garde Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process
Pharmalot By Ed Silverman Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds
Biotech By Damian Garde and Adam Feuerstein FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Biotech By Adam Feuerstein The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
Biotech By Damian Garde Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
Biotech By Jonathan Saltzman — Boston Globe Startup Arkuda targets rapidly advancing, rare form of dementia
In the Lab By Sharon Begley New prize offers $2 million for finding key to Alzheimer’s in past research
Pharmalot By Ed Silverman Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval
Adam's Take By Adam Feuerstein In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way
Pharmalot By Ed Silverman FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak
Pharmalot By Ed Silverman Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause
Signal Podcast By Luke Timmerman and Meg Tirrell Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions
In the Lab By Sharon Begley Their brains had the telltale signs of Alzheimer’s. So why did they still have nimble minds?
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: New bill would create review board for drug prices